Additionally, the 36-month beta value for SAGE is 0.87. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 6 rating it as “overweight,” 16 rating it as “hold,” and 0 rating it as “sell.”
The public float for SAGE is 49.42M and currently, short sellers hold a 12.14% ratio of that float. The average trading volume of SAGE on November 21, 2024 was 682.18K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SAGE) stock’s latest price update
The stock of Sage Therapeutics Inc (NASDAQ: SAGE) has decreased by 0.00 when compared to last closing price of 4.91. Despite this, the company has experienced a -14.31% fall in its stock price over the last five trading sessions. benzinga.com reported 2024-11-20 that On Wednesday, Sage Therapeutics Inc SAGE revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with Huntington’s Disease (HD), an inherited brain disorder that causes nerve cells in the brain to break down and die.
SAGE’s Market Performance
Sage Therapeutics Inc (SAGE) has experienced a -14.31% fall in stock performance for the past week, with a -35.82% drop in the past month, and a -40.05% drop in the past quarter. The volatility ratio for the week is 8.39%, and the volatility levels for the past 30 days are at 7.85% for SAGE. The simple moving average for the past 20 days is -21.19% for SAGE’s stock, with a -59.28% simple moving average for the past 200 days.
Analysts’ Opinion of SAGE
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see SAGE reach a price target of $4, previously predicting the price at $10. The rating they have provided for SAGE stocks is “Sector Perform” according to the report published on October 04th, 2024.
TD Cowen gave a rating of “Hold” to SAGE, setting the target price at $10 in the report published on July 30th of the current year.
SAGE Trading at -27.82% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.63% of loss for the given period.
Volatility was left at 7.85%, however, over the last 30 days, the volatility rate increased by 8.39%, as shares sank -35.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.45% lower at present.
During the last 5 trading sessions, SAGE fell by -14.31%, which changed the moving average for the period of 200-days by -80.14% in comparison to the 20-day moving average, which settled at $6.23. In addition, Sage Therapeutics Inc saw -77.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -3.49 for the present operating margin
- 0.92 for the gross margin
The net margin for Sage Therapeutics Inc stands at -3.17. The total capital return value is set at -0.66. Equity return is now at value -49.34, with -42.95 for asset returns.
Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -3857.27. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -43.01.
Currently, EBITDA for the company is -545.07 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 1.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.02.
Conclusion
In conclusion, Sage Therapeutics Inc (SAGE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
